Search for: "Aventis Pharma SA"
Results 1 - 20
of 31
Sort by Relevance
|
Sort by Date
3 Jan 2019, 5:21 am
C00716606/01 (for the active ingredient sevelamer) and their exclusive licensee Sanofi-Aventis (Suisse) SA enforced their SPC against Swiss pharmaceutical company Salmon Pharma GmbH which had started marketing a generic version of Sanofi-Aventis’ medicament Renvela® containing the active ingredient sevelamer carbonate. [read post]
2 Oct 2011, 8:43 pm
The case involved an application for interlocutory injunctive relief by the owner of Australian patent no. 666859 (the patent), Aventis Pharma SA, and its exclusive licensees, to restrain generic pharmaceutical companies Interpharma and Hospira from threatened infringement. [read post]
3 Aug 2011, 3:31 am
Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet. [read post]
10 Aug 2010, 8:44 pm
Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet. [read post]
21 May 2010, 2:32 am
Two recent examples of disclaimers bolstering bad faith are Sanofi-Aventis, Aventis Pharma SA, Aventis Pharmaceuticals Inc. v. [read post]
18 Mar 2010, 2:30 am
Astellas Pharma US, Inc. [read post]
28 Aug 2009, 8:11 am
., Baxter Healthcare SA v. [read post]
6 Feb 2009, 5:00 am
Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet. [read post]
31 Dec 2008, 6:51 pm
Recent news reports have allowed us to add thirteen biotech/pharma companies and a trade group to the list: • The Pharmaceutical Research and Manufacturers of America (PhRMA), which has more than 30 members including Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Novartis Corp., Pfizer Inc., and Sanofi-Aventis SA, spent more than $5.4 million on third quarter lobbying (see… [read post]
31 Oct 2008, 11:53 am
Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet. [read post]
25 Oct 2008, 12:03 am
Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet. [read post]
5 Sep 2008, 11:01 pm
& Ors v Deisel Spa and Case C-302/08 Zino Davidoff SA v Bendesfinanzdirektion Sudost: (Class 46), EPO Boards of Appeal finds that when a fax is transmitted and an ‘OK’ is noted by the sender, this is evidence that the transmission was successful: (IPKat), Professor Hugenholtz slams European Commission for ignoring evidence on copyright extension: (Techdirt) Germany Federal Patent Court publishes guidelines on colour trade mark Signal Yellow: (Class… [read post]
2 Aug 2008, 12:54 am
, (Daily Dose of IP), 20 August – Bill Patry Copyright Blog speaking on copyright – Melbourne: (Patry Copyright Blog), (LawFont.com), 21 August – Bill Patry Copyright Blog speaking on copyright – Canberra: (Patry Copyright Blog), (LawFont.com), 22 August – Bill Patry Copyright Blog speaking on copyright – Sydney: (Patry Copyright Blog), (LawFont.com), 26 August: WIPO symposium on IP and multilateral agreements – Geneva: (IPKat),… [read post]
18 Jul 2008, 8:34 am
, (Daily Dose of IP), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop – Centurion (South Africa): (Afro-IP), 15-16 September: US ACI 10th advanced forum on biotech patents… [read post]
5 Jul 2008, 11:05 am
: (IP tango), China: Pfizer loses trade mark action against Jaingsu Lianhuan Pharmaceutical Co over 3D mark: (Rouse & Co International), India: More patents for new forms issued to generics: (Patent Circle), India: Gauri Kamath on drug ‘differential pricing’ in India: (Spicy IP), Mexico: Revised health supplies regulations promise changes for generics: (International Law Office), US: World drug pricing crisis: Congressmen criticise US Trade Representative over Special 301… [read post]
13 Jun 2008, 3:40 am
, Schering-Plough Corp – Following dispute over trade dress with Schering-Plough, Fruit of the Earth announces plan to change its package design: (IP Law360), US: Quanta and its impact on biotechnology: (Holman’s Biotech IP Blog), US: BIO files amicus brief asking CAFC to cabin in scope of KSR and hold that its obvious to try dicta does not abrogate the Deuel standard: In re Kubin: (Patently-O), US: StemCells gets patent on enriched central nervous system stem cell and… [read post]
30 May 2008, 9:09 am
– Brdo: (IPR-Helpdesk), 5-6 June: USFDA public meeting on evaluation of product trade names: (FDA Law Blog), 5-7 June: European research and innovation exhibition – Paris: (IPR-Helpdesk), 9-12 June: (US) Strategies for management of IP – Chicago: (IPR-Helpdesk), 11 June: US PLI ‘Advanced patent licensing 2008: What you need to know before licensing your patent’ – San Francisco: (Patent Docs), 11 June: MARQUES ‘First meeting with… [read post]
16 May 2008, 8:03 am
– Brdo: (IPR-Helpdesk), 9-12 June: (US) Strategies for management of IP – Chicago: (IPR-Helpdesk), 16 June / 1 July:US PLI: ‘Prior art & obviousness 2008: The PTO and CAFC perspective on patent law sections 102 & 103’ - San Francisco / New York: (Patent Docs), 17-20 June: US BIO international convention – San Diego: (Patent Docs), 18-20 June / 9-11 July: US PLI: ‘Fundamentals of patent prosecution 2008: A… [read post]
9 May 2008, 10:30 pm
: (Afro-IP), (Managing Intellectual Property), Rwanda: Four years after AIDS drugs bill passed, first low cost meds may head to Rwanda: (GenericsWeb), US: Abbott’s first quarter lobbying tab hits $880,000: (Patent Docs), US: House Bill would expand federal drug pedigree requirements and preempt state requirements: (FDA Law Blog), US: Purchasing Canadian drugs and patent infringement: Litecubes decision: (Patently-O), US: Neuralstem seeks to reopen stayed patent case… [read post]
2 May 2008, 7:00 am
: (Patent Baristas), US: How to avoid a permanent injunction: the lessons of Amgen v Hoffman-LaRoche: (Patent Docs), US: Jarvik Heart’s PTE request based on PMA shell/module submission dates flatlines; ruling on initiation of PTE ‘review period’ mirrors FDA policy for ‘fast track’ products: (FDA Law Blog) Pharma & Biotech - Products Kytril (Granisetron) – Exclusivity ‘parking’ still… [read post]
